anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Poorly controlled anger is a common problem with often devastating effects in Veterans who have served in a warzone. Adverse consequences include increased risk for divorce, domestic violence, job loss and instability, and other serious impairments in family, social, and occupational functioning. Recent evidence indicates that anger and aggression are likely to be problems for a significant proportion of Veterans of Iraq (Operation Iraqi Freedom, OIF; Operation New Dawn, OND) and Afghanistan (Operation Enduring Freedom, OEF). A survey of reintegration problems among 754 OEF/OIF combat Veterans receiving VA Medical care showed that anger was the most commonly reported problem, with 57% reporting increased problems in controlling anger. Despite encouraging evidence for efficacy of cognitive behavioral interventions in treating anger in civilian samples, much less is known about the efficacy of such treatments for anger problems in military personnel following exposure to war zone trauma. Promising preliminary findings for individually based cognitive behavioral treatment have been reported, and there is evidence that a group anger management treatment delivered by teleconferencing is as effective as the same treatment delivered in person, but to date there is not a single adequately powered randomized trial designed to test the efficacy of an anger treatment compared to an active control condition in Veterans. Building on findings from the investigators' randomized pilot study, the objective of the current proposal is to conduct a randomized clinical trial with sufficient statistical power to test the effectiveness of a manualized cognitive behavioral intervention (CBI) that has been adapted from an existing treatment (Anger Control Therapy; Novaco, 1994, 2001) for the treatment of anger problems in OEF/OIF/OND Veterans, compared to a manualized supportive therapy intervention (SI) control condition. Ninety OEF/OIF/OND Veterans reporting significant problems with anger will be randomized to receive 12 individual sessions of one of the two study conditions. Outcomes including measures of anger and aggression; interpersonal, social and occupational functioning; and quality of life will be assessed during and at the end of treatment and at 3 and 6 month follow-ups. Exploratory analyses will examine 1) whether a diagnosis of PTSD impacts treatment effectiveness and 2) potential mediators of treatment outcome with CBI.
Individuals with intellectual and developmental disabilities (IDD) continue to experience disparities in health and well-being despite improved provisions of person-centered care. Patient-centered outcomes research (PCOR) translates evidence into practice for meaningful outcomes. This piece describes findings from an environmental scan and stakeholder outreach to identify and prioritize opportunities to enhance IDD PCOR data infrastructure. These opportunities include developing a standardized research definition; advancing data standards for service systems; improving capture of IDD at point of care; developing standardized outcome measures; and encouraging Medicaid data use for IDD research. Within this piece, we discuss the implications of addressing data gaps for enhanced research. While the identified activities provide a path towards advancing IDD PCOR data infrastructure, collaborative efforts between government, researchers, and others are paramount.
The present invention relates to an acoustic contrast which belongs to a diagnostic drug for cardiovascular diseases. Urea oxygen CH4N2O. H2 O2 is used as the acoustic contrast agent, a clathration reaction is carried out on urea and hydrogen peroxide according to a proportion of (1 to 4M) to 1M, and then, the urea and the hydrogen peroxide are filtered, crystallized and dried. During visualization, physiological saline or dextrose is used for preparing 4 to 6% of a urea oxygen solution so as to carry out vein push injection, and each push injection quantity is 0.1 to 0.5 ml. A plurality of clinical tests indicate that the urea oxygen is used for the acoustic contrast of angiocarpy. The present invention has the advantages of good development effect, result coinciding with the acoustic contrast after operation diagnosis, convenient use, safety, few side effects and low expense, and is an ideal acoustic contrast. The present invention is worthy of popularization and application.
Progesterone receptor (PR) expression has been considered a biomarker of oestrogen receptor-α (ERα) activity. This longstanding relationship has been recently challenged and instead of being merely an ERα-induced gene target, PR may be a critical determinant of ERα activity. The functional significance of this steroid receptor crosstalk is regulation of a gene expression program associated with low tumorigenicity; hence, better disease outcome. Genomic alterations in the PR genomic locus seem to be a relatively common mechanism for reduction of PR expression, which may consequently lead to altered ERα chromatin binding and target gene expression patterns that increase breast tumorigenicity and confers a poor clinical outcome. This ERα-PR crosstalk may be directly influenced by many variables, including the relative receptor levels and the hormonal milieu.

ER-positive advanced breast cancer is a heterogeneous group of diseases with considerable variability in outcome to a range of treatments. Prior response predicts the likelihood of subsequent benefit from another endocrine agent and this should be taken into account in the treatment decision process when assessing whether to prescribe a subsequent endocrine therapy. Despite the enormous progress made regarding the elucidation of breast cancer subgroups and their molecular drivers, most information comes from primary tumors. MA lacks cross-resistance and is active after acquired resistance to potent AI. This pilot trial evaluates in vivo MA modulation of steroidal receptors in advanced breast cancer.
Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.
TIVORBEX (indomethacin) capsule is a nonsteroidal anti-inflammatory drug, available as hard gelatin capsules of 20 mg and 40 mg for oral administration. The chemical name is 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid. The molecular weight is 357.8. Its molecular formula is C19H16ClNO4, and it has the following chemical structure. 

Indomethacin is a white to yellow crystalline powder. It is practically insoluble in water and sparingly soluble in alcohol. Indomethacin has a pKa of 4.5 and is stable in neutral or slightly acidic media and decomposes in strong alkali.

The inactive ingredients in TIVORBEX include: lactose monohydrate, sodium lauryl sulfate, microcrystalline cellulose, croscarmellose sodium and sodium stearyl fumarate. The capsule shells contain gelatin, titanium dioxide, and dyes FD&C blue #1, FD&C blue #2 and FD&C red #40. The imprinting on the gelatin capsules is white edible ink. The 20 mg capsules have a dark blue body imprinted with IP-201 and light blue cap imprinted with 20 mg in white ink. The 40 mg capsules have a dark blue body imprinted with IP-202 and blue cap imprinted with 40 mg in white ink.
Anaphylactic-like reactions characterized by chills, fever, tachycardia, bronchospasm, dyspnea and/or hypotension have been reported to occur in 0.7% to 2% of patients receiving intravenous etoposide and in less than 1% of the patients treated with the oral capsules. These reactions have usually responded promptly to the cessation of the infusion and administration of pressor agents, corticosteroids, antihistamines or volume expanders as appropriate; however, the reactions can be fatal. Hypertension and/or flushing have also been reported. Blood pressure usually normalizes within a few hours after cessation of the infusion. Anaphylactic-like reactions have occurred during the initial infusion of etoposide.

Facial/tongue swelling, coughing, diaphoresis, cyanosis, tightness in throat, laryngospasm, back pain and/or loss of consciousness have sometimes occurred in association with the above reactions. In addition, an apparent hypersensitivity-associated apnea has been reported rarely.

Rash, urticaria, and/or pruritus have infrequently been reported at recommended doses. At investigational doses, a generalized pruritic erythematous maculopapular rash, consistent with perivasculitis, has been reported.
Patients receive CI-CLAM consisting of cladribine and cytarabine via CIV on days 1-2, 1-3, 1-4, 1-5, or 1-6 depending on dose level assignment, and mitoxantrone via CIV on days 1-2 or 1-3 depending on dose level assignment. G-CSF may be added at the discretion of the treating physician, as per standard of care. Patients that do not achieve a response of MRD-negative CR after the first cycle are eligible to receive a second cycle of CI-CLAM. Treatment continues for 2 cycles in the absence of disease progression or unacceptable toxicity.
Poria cocos in the present prescription is sweet and bland, having the benefits of strengthening spleen, tonifying qi, and removing humidity. Poria cocos can also enable people to have diarrhoea without hurting zheng. Angelica sinensis is bitter, warm and smooth, having the benefits of enriching blood, invigorating the circulation of blood, nourishing without stopping. Teaset root heals fracture, nourishes liver and kidney, and strengthens muscles and bones. Rhizoma drynariae can invigorate the circulation of blood and renews injury, nourishes kidney and strengthens bones. Dogwood nourishes liver kidney yin. Radix paeoniae alba and liver blood nourish muscles. Fructus aurantii regulates qi, and makes qi unobstructed. The prescription comprising said components can be applied to bone healing delayed by insufficiency of liver and kidney in the later stage of fracture. Four capsules should be taken orally (each capsule being 0.25 gram) at one time, twice a day.
A chimeric amino acid analogue is provided suitable for incorporating into peptides which compound is represented by formula (1) where P1? and P2? are preferably an amine protecting agents, or P2? may be a protected aminoiminomethyl group, n is 1 and X can be OH, halide, or preferably an activating group suitable for conjugating the compound of formula (1) to a peptide by conventional means. Peptides containing the chimeric amino acid analogue are provided and include a platelet-aggregation inhibitor represented by Aaa1?-Cpd1-Gly-Asp-Aaa2? where Aaa1? is Gly or H, Cpd1 is the compound of formula (1) which has been deprotected and Aaa2? is a hydrophobic amino acid, preferably Val. Alternatively, Aaa1? and Aaa2? may be linked through a structure to form a cycle.
Trauma to perineal area is one of common problems faced by obstetricians affecting physical, social and mental wellbeing of patients. (Perumal D. et al. 2017) During labor, surgical incision to perineum (episiotomy) is done to facilitate delivery of fetus. (Arulkumaran S. et al 2012) Episiotomy is associated with complication such as hemorrhage, infection, pain and wound breakdown. (Sule ST et al. 2003) Pain relief after episiotomy is primary concern of obstetrician and right of patient. (Brennan F. et al. 2007) Pain after delivery causes delayed mobility of patient, late initiation of breast feeding and may affect mother psychologically.

Suturing of episiotomy is done adhering to basic surgical principles of providing good pain control. (Sultan AH et al. 2014) Traditionally local analgesia using xylocaine is being used during episiotomy and repair. Despite this patients do complain of pain in postpartum period which seems less adequate for patients. One study compared infiltration of bupivacaine and lignocaine for episiotomy and found out that patients with lignocaine had higher pain score at 2, 4, and 6 h after the repair. (Abu-Zaida A. et al. 2021) One meta-analysis also determined that pain was lower with bupivacaine compared to lignocaine after episiotomy. (Fyneface Ogan S et al. 2006) Therefore it is necessary to determine other complementary methods to provide adequate pain relief after episiotomy.

Magnesium sulphate is readily available in obstetric units due to its diverse uses, wide safety margins and cost-effectiveness. Magnesium is a calcium channel blocker and noncompetitive N methyl D aspartate (NMDA) receptor antagonist with anti-nociceptive effects. Blocking of NMDA receptors inhibits central sensitization due to peripheral nociceptive stimulation. (Akhtar MI et al. 2011) Furthermore, there are peripheral NMDA receptors in the muscles, skin, and knee joints that play a role in sensory transmission of noxious signals. The nociceptors release glutamate in response to an afferent signal that binds to NMDA receptors leading to nerve depolarization and heightened sensitivity to circulating neurotransmitters. Magnesium sulphate inhibits these receptors thus producing anti-nociceptive effect. The addition of Magnesium sulphate to local anesthetics for neuraxial anesthesia prolongs the duration of anesthesia and improves the quality of analgesia. (Abd Elsalam KA et al. 2017)

The role of magnesium has been evaluated as adjuvant for intra- and post-operative pain relief in orthopedic, gynecological, and thoracic surgeries and has established role in anesthesia and obstetrics. (Akhtar MI et al. 2011) Moreover studies have determined that subcutaneous infiltration of Magnesium sulphate with local anesthetic after caesarean section prolongs the analgesic efficacy of local anesthetic without any significant adverse effects. (Kundra S et al. 2016) One recent study comparing the effects of using local infiltration of lignocaine only and lignocaine with magnesium after episiotomy sulfate determined that patients have significant pain relief after 2 hours with combination of lignocaine and magnesium sulfate. (Garba JA et al. 2021)
If after four (4) weeks of diet modification, patients are still experiencing migraines, they may be randomized to topiramate for eight (8) weeks. If still experiencing symptoms, they will receive nortriptyline for eight (8) weeks.
Patients receive bortezomib IV on days 1, 8, and 15. Treatment repeats every 28 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.
In this group, the participants performing PVC carried out the procedure by observing vein dilation after isometric exercise. Before the procedure, the students on whom PVC was to be performed were given two stress balls, and they were told how to use them for 15 minutes. The stress balls used in the study were 6 cm in diameter and yellow in color. They were of medium hardness and made of high-quality silicone. The participants were told to squeeze and relax the stress ball in the palm of their hands after counting from one to three, to continue doing this until the procedure began, and to concentrate on squeezing the ball. Participants were asked about the degree of vein prominence after the isometric exercise and tourniquet was applied, using inspection and palpation. The remaining stages were carried out in the same way as with all of the groups.
BACKGROUND: Overactive bladder (OAB) affects one in six adults in Europe and the United States and impairs the quality of life of millions of individuals worldwide. When conservative management fails, third-line treatments including tibial neuromodulation (TNM) is often pursued. TNM has traditionally been accomplished percutaneously in clinic.
OBJECTIVE: A minimally invasive implantable device activated by a battery-operated external wearable unit has been developed for the treatment of urgency urinary incontinence (UUI), mitigating the burden of frequent clinic visits and more invasive therapies that are currently commercially available.
METHODS: A prospective, multicenter, single-arm, open-label, pivotal study evaluated the safety and effectiveness of the device in adult females with UUI (i.e., wet OAB) (BlueWind Implantable Tibial Neuromodulation [iTNM] system; IDE number #G200013; NCT03596671). Results with the device were previously published under the name RENOVA iStim, which has been since renamed as the Revi™ System. Approximately 1-month post-implantation of the device, participants delivered therapy at their convenience and completed a 7-day voiding diary before visits 6- and 12-months post-treatment initiation. The primary efficacy and safety endpoints were the proportion of responders to therapy ( ≥ 50% improvement on average number of urgency-related incontinence episodes) and incidence of adverse events from implantation to 12-month post-activation.
RESULTS: A total of 151 participants, mean age 58.8 (SD: 12.5), were implanted; 144 and 140 completed the 6- and 12-month visits, respectively. The participants demonstrated mean baseline of 4.8 UUI/day (SD 2.9) and 10 voids/day (SD 3.3). Six and 12-months post-activation, 76.4% and 78.4% of participants, respectively, were responders to therapy in an intent-to-treat analysis. Of the 139 participants with completed 12-month diaries, 82% were responders, 50% were classified as "dry" (on at least 3 consecutive diary days), and 93.5% of participants reported that their symptoms improved. No implanted participant experienced an SAE related to the procedure or device.
CONCLUSIONS: iTNM, delivered and powered by a patient-controlled external wearable communicating with an implant, demonstrated clinically meaningful and statistically significant improvement in UUI symptoms and a high safety profile. This therapy highlights the value of patient-centric therapy for the treatment of UUI.
The invention comprises compounds of the general formula <FORM:1000896/C2/1> in which n1 and n2 each represent zero or unity, X represents a hydroxy, alkoxy, amino or hydrazino group or an alkylamino or dialkylamino group which may be long-chain in character (i.e. containing at least 10 carbon atoms) and each R represents a residue of an a -amino carboxylic acid devoid of its a -amino and carboxylic groups with at least one such residue carrying an amino and/or guanidino group which may in turn carry a long-chain aliphatic acyl substituent and in which A represents an amino group or an amino group which carries a long-chain acyl substituent, and acid addition salts thereof; there being at least one of said long-chain moieties present in the molecule and the preparation thereof by condensing the appropriate protected a -amino carboxylic acid with a protected a -amino acid or dipeptide or tripeptide or the appropriate protected dipeptide with an a -amino acid or dipeptide in the presence of a condensing agent, or reacting the appropriate protected a -amino carboxylic acid or dipeptide or tripeptide starting material in its mixed anhydride, azide, activated ester, or acid chloride form with the other component in the absence of a condensing agent, hydrolysing the terminal carboxyl function to a free carboxyl group or converting it into an amido, N-alkyl-amido, N,N-dialkylamido or hydrazido group, removing the protective groups, and, if desired, converting the resulting peptide into a salt; the long-chain acyl group, if not already present in the molecule, being effected by interchange with a protecting group which can be selectively split off.  Carboxyl groups are protected prior to the condensation reaction involving them per se by conversion into their esters or amides or by salt formation. Free amino groups may be protected by conversion into benzyloxycarbonylamino groups by formylation, or by conversion into phthalyl derivatives or by the introduction of the long-chain acyl group.  Compounds may contain more than one N-protecting group and if these are different the groups may be removed separately.  Na  - Palmitoyl - (Nd  - carbobenzyloxy) - L-ornithine is prepared from the N-protected ornithine and palmitoyl chloride Na -palmitoyl-Ne -carbobenzyloxy-L, -D- and -DL-lysine; Na -stearyl-,-lauryl-, and -caproyl-Ne -carbobenzyloxy-L - lysine, and Na  - palmitoyl - Na  - carbobenzyloxy - L - diamino butyric acid.  Ne -Palmitoyl-L-lysine methylester is prepared by reacting the copper complex of L-lysine with palmitoyl chloride to give Ne -palmitoyl-L-lysine and esterifying this with methanol.  Similarly is prepared Na -palmitoyl L-diamino-butyric and its methyl ester.  Ne -Phthaloyl-L-lysine ethyl ester hydrochloride prepared from the free acid is reacted with 10-andecenoic acid in the presence of dicyclohexyldicarbodimide to give Na  - (10 - undecenoyl) - (Ne  - phthaloyl) - L lysine ethyl ester and, on hydrolysis, the free acid.  Na  - Benzyloxycarbonyl - Ne  - phthaloyl-L-lysine is prepared from the Ne -phthaloyl-L-lysine and benzyloxycarbonyl chloride.  Specifications 1,000,899 and 1,000,900 are referred to.
The safety and feasibility of early discharge of low-risk STEMI treated with thrombolysis or PPCI patients have previously been investigated. It is possible to identify a subset of patients with very low risk for subsequent cardiac events in the short-term, where prolonged hospital stay beyond three days does not alter the outcome. Early discharge have however, not been included in STEMI management guidelines formally. The effects of this discharge regimen on STEMI patients' health status (symptoms, functional capacity and quality of life) is not previously investigated. Shorter hospital stays saves health care resources. On the other hand, short in-hospital stay can affect the perceived satisfaction of care. Initiation of medical treatment, patient education, life style counselling and follow-up routines may suffer. Additionally, early discharge can increase anxiety and symptom level reducing the health related quality of life (HRQOL) and also lead to readmission. Patient satisfaction has become a recognised measure of the quality of health care.Currently there is little information on how early discharge influence the patients' satisfaction with the health care or the subjective perceived of HRQOL after discharge. We therefore wish to perform a prospective trial comparing outcomes with regard to satisfaction of care and HRQOL in patients admitted for STEMI randomised to either early discharge or standard care.
This is a multicenter, open-label (identity of treatment is known to patient's parent/legal guardian/caregiver and to all study staff) pharmacokinetic study (a study to observe how the drug is absorbed and distributed within the body) to measure drug levels of doripenem in hospitalized but medically stable infants (term and preterm), \<12 weeks of chronological age (CA) (age since time of birth) who have documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with intravenous (i.v.) (administered in a vein) antibiotics. Doripenem will be administered alone at any time after the first dose of a nonstudy antibiotic is administered to the patient. Doripenem is not being used in this study to treat infection and it will not replace the patient's prescribed antibiotic(s). The duration of the study will be up to 9 days for each patient. Patients' safety will be monitored throughout the study by a safety committee who will review safety information at least once a month or after every 8 patients are enrolled and dosed. Safety evaluation will include, but will not be limited to, adverse events, clinical laboratory tests, and vital signs. A single dose of study drug (doripenem) will be administered to patients in a hospitalized setting. Patients \<8 weeks CA will receive a 5 mg/kg doripenem 1-hour i.v. infusion, and patients \>=8 weeks CA will receive an 8 mg/kg doripenem 1-hour infusion. Study drug will be administerd to the patient alone at any time after the first dose of a nonstudy antibiotic is administered to the patient.
The intervention will be performed by a physical therapist, which will consist of preparatory labor kinesiotherapy, which aims to prepare the workers' osteo-articular system for the beginning of the work activity, acting more specifically on those muscle groups that will be most required during the journey which will be identified in the evaluation. Labor kinesiotherapy will be performed in the workplace before the workday and will last 20 minutes, 3 times a week, for 12 weeks.